

All approved abstracts **EXCLUSIVE** Case Reports and Trials in Progress will be published in the online supplement issue of **NEUROENDOCRINOLOGY** subsequent to the conference.

All approved abstracts **INCLUSIVE** Case Reports and Trials in Progress will be presented in the poster exhibition in the exhibition hall and in **MY ENETS** after the conference.

(Media Library, [www.enets.org/my\\_enets](http://www.enets.org/my_enets))

**A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS**

- (A01)\* **Bai JA et al.** Long Noncoding RNA HNF1A-AS1 Targeting Oncostatin M Expression Inhibits Epithelial-Mesenchymal Transition via TGFβ Signaling in Gastroenteropancreatic Neuroendocrine Neoplasms
- (A02) **Blenkiron C et al.** A Spatial Proteomics Approach Identifies Novel Immuno-Oncology Markers for Merkel Cell Carcinoma
- (A03) **Borges de Souza P et al.** Dose and Time-Dependent Effect of Chloroquine on Autophagosome Generation in a Typical Bronchial Carcinoid Cell Line
- (A04) **Bresciani G et al.** EGFR and IGF1R Impair Sunitinib Activity and May Represent Novel Targets for Broncho-Pulmonary Neuroendocrine Neoplasm Treatment
- (A05) **Busse A et al.** Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy
- (A06) **Duschek S et al.** Expression Signature of GEP-NETs in Correlation to Clinical Outcome at ENETS CoE in Switzerland
- (A07) **Herrera-Martínez AD et al.** Efficacy of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells
- (A08) **Jin XF et al.** Combination of 5-Fluorouracil (5-FU) with DNMTs or HDACs as Epigenetic Modifiers Has Synergistic Effects on Radiosensitization and Somatostatin Receptor sstr 2 Expression in Human Neuroendocrine Tumor Cells
- (A09) **Jin XF et al.** The Porcupine (PORCN) Inhibitor WNT974 Exerts Multiple Anticancer Activities in Neuroendocrine Tumor Cell Lines in Vitro
- (A10) **Nakazato M et al.** Development of Diagnostic Biomarkers of Lung Neuroendocrine Tumors by the Detection of Cancer-Derived Protein Fragments in the Urine Using Original Mass Spectrometric Methods
- (A11) **Teufel A et al.** Evaluation of Gene Expression Changes Associated with Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)
- (A12) **Tsuchikawa T et al.** Identification of Novel IgG Type Tumor Marker in Non-Functional Pancreatic Neuroendocrine Tumors by SEREX Method
- (A13) **Wang J et al.** Long Non-Coding RNA CEP170P1 Promotes Malignant Metastasis in Gastro-Enteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
- (A14) **Willemoe GL et al.** Assessment of TP53 Status Using Next Generation Sequencing and Immunohistochemistry in G3 Neuroendocrine and Mixed Neuroendocrine-Noneuroendocrine Neoplasms

**B. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS**

- (B01) **Amin T et al.** Cancer Associated Fibroblasts Stimulate Proliferation and Induce Resistance to Everolimus in Neuroendocrine Tumor Cells
- (B02) **Bresciani G et al.** Available 3D Cultures Methods: Study on a Pancreatic Neuroendocrine Neoplasm Cell Line
- (B03) **Bresciani G et al.** Influence of Tumor Microenvironment in Response Modulation to Treatment in Human Broncho-Pulmonary Neuroendocrine Neoplasm
- PW** (B04) **Dayton T et al.** Using Adult Stem Cell-Derived Organoids to Model Neuroendocrine Neoplasms
- (B05) **Ichikawa Y et al.** Establishment of Patient-Derived Tumor Organoid (PDTO) Derived from Pancreatic Neuroendocrine Tumor
- (B06) **Knigin A et al.** Combined Autophagy and mTOR Inhibition Reduces Cells Proliferation and Induces Apoptosis in a Lung Carcinoid In-Vitro Model
- (B07) **Sedding DJH et al.** Evaluating Novel Inhibition of FOXM1 Signaling Pathways as Targets in Gastroenteropancreatic Neuroendocrine Cells
- (B08) **Yang X et al.** Downregulation of TAK1 Inhibit Migration and Invasion in Neuroendocrine Tumor Cells

\*The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

### C. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS

- OA (C01)** *Alcala N et al. Integrative and Comparative Genomic Analyses Identify Clinically Relevant Groups of Pulmonary Carcinoids and Unveil the Existence of Supra-Carcinoids*
- PW (C02)** *Berner A et al. PUnNETS (Prediction of Unknown Neuroendocrine Tumour Site) – A DNA Methylation-Based Classifier*
- (C03)** *Blazevic A et al. Proteomic Analysis of Small Intestinal Neuroendocrine Tumours and Associated Mesenteric Fibrosis Reveals Primarily Differences in Mesenteric Stroma*
- OA (C04)** *Cros J et al. Genomic Landscape of Pulmonary Carcinoids with High Grade Progression*
- (C05)** *Dou D et al. MicroRNA-202-3p As a Potential Diagnostic Biomarker for Type 1 Gastric Neuroendocrine Tumor*
- (C06)** *Jian-An B et al. Octreotide-Conjugated Core Cross-Linked Micelles with pH/Redox Responsivity Loaded with Etoposide for Neuroendocrine Neoplasms Therapy and Bioimaging with Photoquenching Resistance*
- (C07)** *La Salvia A et al. Extra-Pulmonary Neuroendocrine Carcinomas Display Distinct Transcriptional Profiles According to the Site of Origin*
- PW (C08)** *Mandriani B et al. The Genomic Landscape of Small Nonfunctioning pNETs*
- OA (C09)** *Melchior LC et al. Next Generation Sequencing of 294 Neuroendocrine G3 and Mixed Neuroendocrine and Non-Neuroendocrine Neoplasms Identifies Molecular Profile Linked to the Site of the Primary and Tumor Composition*
- PW (C10)** *Pedraza-Arévalo S et al. Drastic Dysregulation in Splicing Machinery and Its Association with Aggressiveness Features in Pancreatic Neuroendocrine Tumors*
- OA (C11)** *Robb T et al. Understanding Tumour Evolution of a Highly Disseminated Lung NET Through Multi-Player Augmented Reality Visualisation*
- PA (C12)** *Sadanandam A et al. Immune Characteristics of Pancreatic Neuroendocrine Tumors According to Grade and Molecular Subtypes*
- PW (C13)** *Simbolo M et al. Next Generation Sequencing and Transcriptome Analysis Identify Common Genomic Signatures for Atypical Carcinoids and Large Cell Neuro-Endocrine Carcinomas of the Lung*
- OA (C14)** *Sposito T et al. The PanNET-Related Histone H3.3 Chaperone Daxx Regulates Lineage Specification and Tissue Homeostasis in the Pancreas*
- PW (C15)** *Tirosh A et al. Distinct Genome-Wide Methylation Patterns in Sporadic and Hereditary Nonfunctioning Pancreatic Neuroendocrine Tumors*
- PW (C16)** *Vicentini C et al. Distinct Transcriptional Signatures of ATRX and DAXX Mutated PanNETs*
- (C17)** *Wang Z et al. Uncovering the Heterogeneous Genetic Variations in Two Insulin-Expressing Tumors in a Patient with MEN1*

### D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS

- (D01)** *Altieri B et al. Natural History and Prognostic Factors of Survival in Localized and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Resection: A Multicenter Study Among Italian and French ENETS Centers*
- (D02)** *Bai JA et al. Clinical Features of Rectal Neuroendocrine Neoplasms and Risk Factors for Metastasis*
- OA (D03)** *Blazevic A et al. Influence of Gender on the Evolution of Mesenteric Metastases in Small Intestinal Neuroendocrine Tumours*
- (D04)** *Bottiglieri F et al. Pitfalls in Diagnosis of Insulinomas: Multidisciplinary and Experienced Approach*
- (D05)** *Boumansour NFZ et al. Epidemiological Profile of Neuroendocrine Tumors in Western Algeria 2017-2018*
- (D06)** *Brabo EP et al. Clinical Presentation and Diagnostic Delay in a Series of MEN1 Patients in Brazil*
- (D07)** *Brabo EP et al. Survival Outcomes of Extra Pulmonary Neuroendocrine Carcinomas in a Single Center in Brazil*
- (D08)** *Buikhuisen W et al. Association between Pulmonary Carcinoids (PC) and Other Types of Cancer*
- (D09)** *Chraiet N et al. Neuroendocrine Tumors: A 20-Years' Experience of the Salah Azaiez National Cancer Institute in Tunisia*
- (D10)** *Clement D et al. NET Patients' Report Significant Time to Diagnosis from Onset of Symptoms*
- (D11)** *Cosaro E et al. Clinico-Pathological Features, Treatment Modalities and Prognosis of Patients with Malignant Insulinoma: Preliminary Data From a Multicentre Study*

- (D12) **Cuypers A et al.** Neuroendocrine Neoplasms Grade 3: Prospective Overall Survival Data and Survival after Platinum-Etoposide Chemotherapy within an ENETS Center of Excellence
- (D13) **Darden C et al.** Satisfaction Survey of Administration Modes for Long-Acting (LA) Somatostatin Analog (SSA) Therapy in Patients (pts) with Neuroendocrine Tumors (NETs): Results of Cognitive Interviews with Patients and Nurses
- (D14) **De Cicco F et al.** Neuroendocrine Tumors in Elderly: Clinical Presentation, Prognosis and Therapy
- (D15) **De Groot E et al.** Overview of Neuroendocrine Patient Demographics and Outcomes in the Leicestershire Region
- (D16) **Devlin L et al.** Neuroendocrine Tumour (NET) Patients Experiences of Support in the Community Setting Across the Cancer Treatment Trajectory
- (D17) **Exarchou K et al.** Endoscopic Surveillance Is a Viable Alternative Management Strategy for Patients with Localised Small Non-Functional Low Grade Duodenal Neuroendocrine Tumours (dNETs)
- (D18) **Fan JH et al.** Clinical Epidemiology Study of Gastric Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study
- (D19) **Fatima A et al.** Evaluating the Impact of Treatment, Disease Burden and Disease Status on Quality of Life among Patients Diagnosed with Neuroendocrine Tumors
- (D20) **Furtado O'Mahony L et al.** Combination of 68Ga-DOTATATE and 18F-FDG PET/CT in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNET) - Clinical and Prognostic Implications
- (D21) **Furtado O'Mahony L et al.** Utility of 68Ga DOTATATE PET in Challenging Neuroendocrine Neoplasms' Scenarios
- (D22) **Gao H et al.** The Distinct Clinicopathological and Prognostic Features of Insulinoma with Synchronous Distant Metastasis
- (D23) **Glaser JM et al.** Incidence of Secondary Malignoma in Patients with Gastro-Enteropancreatic Neuroendocrine Neoplasia
- (D24) **Goudet P et al.** Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1. A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne)
- (D25) **Hadoux J et al.** Characteristics and Outcome of Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC) Occurring in Previously Irradiated Areas
- (D26) **Hayes AR et al.** Metastases to the Breast in Patients with Metastatic Neuroendocrine Tumours (NET) Clinicopathological and Imaging Characteristics
- (D27) **Heidsma C et al.** The PANDORA Study, A Prospective Cohort of Conservatively Treated, Non-Functional Pancreatic Neuroendocrine Tumors < 2 cm
- PW** (D28) **Jimenez-Fonseca P et al.** Nomogram to Predict Progression-free Survival in Patients with Well-differentiated, Stage IV Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues: Data of TRASGU-GETNE Study
- PW** (D29) **Kamieniarz L et al.** Diagnostic Features and Management Options for Duodenal (Non-Ampullary) Neuroendocrine Neoplasms: Results from a Multi-Centre Series
- (D30) **Kamieniarz L et al.** Orbital Metastases from Neuroendocrine Tumours: Epidemiology and Clinical Implications
- (D31) **Khalil M et al.** Is the Cystic Character of a Pancreatic Neuroendocrine Tumor a good Prognosis Factor?
- (D32) **Khan M et al.** Improving Patient Outcomes: Development of a Patient-Centred Service for Neuroendocrine Tumours in Wales through Population-Based National Commissioning
- (D33) **Koca E et al.** Establishment of a NET Data Base in a German Tertiary Referral Center Preliminary Results
- PW** (D34) **Kolarova T et al.** Unmet Needs in Global Neuroendocrine Tumour (NET) Care: Similarities and Differences in the Perspectives of Patients, Patient Advocates and NET Health Professionals
- (D35) **Kooyker A et al.** Change in Incidence, Characteristics and Management of Colorectal Neuroendocrine Tumors in the Netherlands in the Last Decade
- OA** (D36) **Kuiper T et al.** Endoscopically Removed Colorectal NETs; A Nationwide Cohort Study
- (D37) **Leigh C et al.** Myocardial Metastases in Neuroendocrine Tumours: Epidemiology and Clinical Implications
- (D38) **Lider Burciulescu SM et al.** The Response in Patients with Pheochromocytoma to the Antihypertensive Drugs Correlated with the Values of the Catecholamine and with Mutation
- (D39) **Magi L et al.** Presentation and Multidisciplinary Management of Neuroendocrine Neoplasia
- (D40) **Mandal N et al.** Psycho-Social Problem: My Time with Cancer

- (D41) **Mazza M et al.** Management of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors: From Guidelines to Real Life
- (D42) **Michael M et al.** Incidence, Prevalence and Survival Trends for NETs/NECS in Victoria, Australia, from 1982-2016: Based on Site, Grade and Region
- (D43) **Modica R et al.** Duodeno Pancreatic Neuroendocrine Tumors (DPNET) in Multiple Endocrine Neoplasia Type 1 (MEN1): An Italian Restrospective, Observational, Multicenter Study
- (D44) **Murgioni S et al.** Neuroendocrine Neoplasm in Real World Practice: A Large and Modern Single Institution Experience
- (D45) **Parker K et al.** The NETwork! Registry Analysis Supports the WHO 2017 Classification in the First NET Specific Survival Analysis for a Complete Population
- (D46) **Pellé E et al.** An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs
- (D47) **Peralta Ferreira M et al.** Gastric Neuroendocrine Tumors Workup – Classification and Treatment Challenges
- (D48) **Pranoy S et al.** Evaluation of Nutritional Deficiencies in a New Gastroenterology-led South Wales Neuroendocrine Tumour (NET) Service
- (D49) **Rinzivillo M et al.** Prognostic Impact of Tumor Burden In Stage IV Neuroendocrine Neoplasia: A Comparison Between Pancreatic and Gastrointestinal Localizations
- (D50) **Rinzivillo M et al.** Tumor Type and Size Are Prognostic Factors in Gastric Neuroendocrine Neoplasia: A Multicentre Retrospective Study
- (D51) **Rossi RE et al.** Second Primary Malignancies in Patients with Gastro-Entero-Pancreatic Neuroendocrine Neoplasia (GEP-NEN)
- (D52) **Santos AP et al.** Obesity and Metabolic Syndrome Don't Seem to Influence Progression Free Survival in Well Differentiated GEP-NETs
- (D53) **Siebenhüner A et al.** Treatment Landscape of GEP-NETs in Correlation to Clinical Outcome at ENETS CoE in Switzerland
- (D54) **Song L et al.** A Retrospective Analysis of 117 Patients with Esophageal Neuroendocrine Tumors
- (D55) **Song L et al.** Clinical Analysis on 547 Patients with Neuroendocrine Tumors in a Chinese Population: A Single-Center Study
- (D56) **Tanno L et al.** What Is the Burden of Treatment in Patients with Small Bowel Neuroendocrine Tumour? A UK Regional Single Centre Experience
- (D57) **Tarquini M et al.** Evaluation of NEP-SCORE Applicability in a Series of Patients with IV Stage NEN
- (D58) **Uema D et al.** High Tumor Burden and Treatment in the Public Setting Are Associated with Carcinoid Heart Disease and Decreased Overall Survival: A Multicenter and Multinational Study
- (D59) **Van Beek DJ et al.** Prognostic Factors and Survival in MEN1 Patients with Gastrinomas: Results from the DutchMEN Study Group (DMSG)
- (D60) **Whyand T et al.** The Essential Role of Functional Nutrition Assessment in NET Clinics
- (D61) **Wyld D et al.** Incidence and Survival of Small Intestinal Neuroendocrine Tumours in Queensland, Australia, 2001-2015
- (D62) **Yalcin S et al.** Gastroenteropancreatic Neuroendocrine Tumors (GEPNET) Registry 2009-2018: Results of Collaborative Effort Including over 1000 Patients (Pts) with GEPNET from 15 Countries
- (D63) **Zhang S et al.** Clinicopathological Characteristics and Prognostic Predictors of Gastroenteropancreatic Neuroendocrine Neoplasms: A Nation-Wide 10-Year Retrospective Study in China

#### E. PATHOLOGY - GRADING, STAGING

- (E01) **Chiranth DJ et al.** Incidence and Clinicopathological Features of Colorectal Neuroendocrine Carcinomas and Mixed Neuroendocrine-Nonneuroendocrine Neoplasms
- (E02) **De Barros E Silva MJ et al.** Ki-67 Index as a Useful Tool to Distinguish Different Evolution and Clinicopathological Features in Normogastrinemic Gastric Neuroendocrine Tumors
- (E03) **Emelianova G et al.** Value of Re-Biopsy of Liver Metastases of Patients with Neuroendocrine Tumors in Disease Progression
- (E04) **Kasajima A et al.** Prognostic Impact of Ki-67 Index and WHO2017 Classification in Bronchopulmonary Neuroendocrine Neoplasm
- (E05) **Rubino M et al.** Lung Carcinoid with High Proliferation Index (G3 lung NET): Frequency, Prognosis and Response to Systemic Therapy

- (E06) **Waldum H et al.** Hepatic Neuroendocrine (NE) Micrometastases Outside Macrometastases Are Found in All Patients with Ileal Primary Tumour at the Time of Liver Resection
- (E07) **Zhang P et al.** Clinicopathological Features and Metastatic Patterns of Patients with Gastroenteropancreatic Mixed Adenoneuroendocrine Carcinoma

**F. BIOMARKERS**

- (F01) **Abudureheyimu N et al.** Correlation Analysis between Neuroendocrine Neoplasm and Immunophenotype Expression in Different Sites
- (F02) **Andreasi V et al.** Association between Preoperative Vasostatin-1 and Pathological Features of Aggressiveness in Localized Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
- (F03) **B XL et al.** Comprehensive Genomic Profiling of Chinese Patients with Neuroendocrine Neoplasm
- (F04) **Bodei L et al.** Circulating Neuroendocrine Tumor Gene Expression for Monitoring Peptide Receptor Radionuclide (PRRT) Efficacy
- PW** (F05) **Botling J et al.** Longitudinal Increase in Ki-67 and High-Grade Transformation in Pancreatic Neuroendocrine Tumors (PNETs)
- (F06) **Chan D et al.** Computed Tomography (CT) - Defined Sarcopenia Is Prevalent in Patients with Neuroendocrine Neoplasms (NENs)
- (F07) **Ewang-Emukowhate M et al.** Assessment of Fat-Soluble Vitamins and Trace Elements in Patients with Neuroendocrine Tumours (NET) on Somatostatin Analogues (SSA)
- (F08) **Fatima A et al.** Finding the Link between Transforming Growth Factor  $\beta$ -1 (TGF $\beta$ -1) and Neuroendocrine Tumor Cells. A Role in Carcinogenesis
- (F09) **Fatima A et al.** The Need of NET Diagnostic Biomarkers for Early Detection and Targeted Management. Should Biomarkers Reflect Disease Progression?
- (F10) **Grønbaek H et al.** Relationship between Biomarkers and Number of Liver Metastases at the Time of Diagnosis of Small Intestinal Neuroendocrine Tumors
- (F11) **Gurevich L et al.** Prognostic Value of Decreased Membrane Expression NDRG1 in Neuroendocrine Tumors of Different Localization and Degree of Malignancy
- (F12) **Halfdanarson T et al.** Impact of Continuous and Categorical Covariates on the Determination of 5-Hydroxyindoleacetic Acid in Urine
- (F13) **Hermans B et al.** DLL3 in Large Cell Neuroendocrine Carcinoma (LCNEC) Associated with Molecular Subtypes
- (F14) **Laskaratos F et al.** Circulating Transcript Analysis (NETest) Assessment in the Follow-up (F/U) of Resected Midgut Neuroendocrine Tumours (NETs)
- (F15) **Laskaratos F et al.** Circulating Transcripts of Profibrotic Genes in the NETest Can Identify Mesenteric Fibrosis in Midgut Neuroendocrine Tumours (NETS)
- (F16) **Liu Z et al.** A Retrospective Analysis of PD-1/PD-L1 and DNA Mismatch Repair Proteins Expression in Neuroendocrine Neoplasms
- (F17) **Liu Z et al.** A Retrospective Analysis of SSTR2 and MGMT Expression in Neuroendocrine Neoplasms
- (F18) **Malczewska A et al.** NETest Is Diagnostic for Gastric NETs and Identifies Microscopic and Macroscopic Disease
- (F19) **Malczewska A et al.** NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
- (F20) **Malczewska A et al.** Validation of the NETest as a Diagnostic for Rectal Neuroendocrine Tumors
- (F21) **Malczewska A et al.** Validation of the NETest Liquid Biopsy as a Diagnostic for Small Intestine and Pancreatic Neuroendocrine Tumors
- (F22) **Meyer T et al.** Exploratory Assessment of the Clinical Value of Baseline (BL) Circulating Tumour Cells (CTC) to Predict Symptomatic Response in Pts with Functioning Midgut Neuroendocrine Tumours (NETs) Receiving Lanreotide Autogel (LAN): CALM-NET Study Results.
- PW** (F23) **Modlin I et al.** Automated Finger Prick Blood Genomic Diagnosis of Neuroendocrine Tumors
- (F24) **Oleinikov K et al.** ProGRP Is an Effective Marker for Disease Monitoring in Lung Carcinoids with Non-Informative Chromogranin A: Lessons from Clinical Practice
- (F25) **Tsolakis A et al.** Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel IHC Markers

### G. IMAGING AND INTERVENTIONS (RADIOLOGY, ENDOSCOPY)

- (G01) **Fine C et al.** Endoscopic Management of 345 Small Rectal Neuroendocrine Tumours: A National Study from the French Group of Endocrine Tumours (GTE)
- (G02) **Izaaryene J et al.** Transarterial Chemoembolization of Liver Metastatic Neuroendocrine Tumors
- (G03) **Lamarca A et al.** Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study
- (G04) **Lazaridis N et al.** Endoscopic Submucosal Dissection (ESD) of Gastric and Rectal Neuroendocrine Tumours (NETs)
- (G05) **Rinzivillo M et al.** Texture Analysis on Contrast-Enhanced Computed Tomography in Liver Metastases from Pancreatic and Non-Pancreatic Neuroendocrine Neoplasia
- (G06) **Trifanov V et al.** Experience in Treatment of Hepatic Metastases of Neuroendocrine Tumors Using Transarterial Chemoembolization

### H. MEDICAL TREATMENT - CHEMOTHERAPY SOMATOSTATIN ANALOGUES, INTERFERON

- (H01) **Bengueddach A et al.** Capecitabine Temozolomide Efficacy and Tolerability in Metastatic Neuroendocrine in G2 Neuroendocrine Neoplasm
- (H02) **Bengueddach A et al.** Primitive Mammary Neuroendocrine Tumor: About Two Rare Cases
- (H03) **Brighi N et al.** Biliary Stone Disease in Patients Receiving Somatostatin Analogs for Neuroendocrine Neoplasms (NEN): An Italian Multicenter Study
- (H04) **Brighi N et al.** Non-Conventional Doses of Somatostatin Analogs in Well-Differentiated NET Patients at Disease Progression (PD) on RECIST Criteria: An Italian Multicenter Analysis
- (H05) **Chan D et al.** Temozolomide in Grade 3 Neuroendocrine Neoplasms (G3 NENs): A Multicentre Retrospective Review
- (H06) **Chatzellis E et al.** Efficacy and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
- (H07) **De Mestier L et al.** Comparison of Temozolomide-Capecitabine to 5-Fluorouracil-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses
- (H08) **De Mestier L et al.** Temozolomide (TEM) vs Temozolomide-Capecitabine (CAP) in Advanced Pancreatic NET (pNET): A Multicenter Retrospective Analysis of 138 Patients Using a Propensity Score
- OA** (H09) **Elvebakken H et al.** A Consensus Developed Morphological Re-evaluation of 196 Cases with Metastatic High-grade Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN G3) from the Nordic NEC Registries: Consequences for Classification, Treatment Response and Survival
- (H10) **Giroit P et al.** Oxaliplatin and 5-Fluorouracil (FOLFOX) in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A National Retrospective Study from the French Group of Endocrine Tumors (GTE)
- (H11) **Granja Ortega M et al.** Non-Functioning Neuroendocrine Tumors Treated with Somatostatin Analogs on the Frontline: Management after Progression in Clinical Practice
- (H12) **Mao R et al.** Effectiveness of Adjuvant Chemotherapy for Patients with Poorly Differentiated Colorectal Neuroendocrine Carcinomas: A Study of the National Cancer Database
- (H13) **Markovich A et al.** Experience of Long-Acting SSA Administration in Patients with Well-Differentiated Gastro NETs
- (H14) **Martin W et al.** Development of a New and Improved Delivery System (DS) for Lanreotide Autogel/Depot (LAN) to Further Enhance Patient Care
- (H15) **McGarrah P et al.** Comparative Efficacy of 2nd-Line Chemotherapy Regimens in Extrapulmonary Poorly-Differentiated Neuroendocrine Carcinoma (PD NEC): The Mayo Clinic Experience
- (H16) **Oziel-Taieb S et al.** Outcome Analysis of FOLFOX Chemotherapy Treatment in Metastatic Neuroendocrine Tumors
- (H17) **Pavel M et al.** Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
- PW** (H18) **Prasad V et al.** Tumour Growth Rate (TGR) to Monitor Growth/Predict Response to Lanreotide Autogel (LAN) Use before, during and after Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Data from PRELUDE
- (H19) **Pusceddu S et al.** Post-Hoc Analysis of CLARINET Phase III Study to Investigate the Influence of Diabetic Status on Progression-Free Survival (PFS) of Patients with Neuroendocrine Tumours (NETs) Treated with Lanreotide (LAN) or Placebo (PBO)

- (H20) **Reher D et al.** Response of the Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Treated with Streptozotocin/5-FU – A Preliminary Retrospective Study
- (H21) **Scala S et al.** IMMUNeOCT: Octreotide LAR in the Induction of Immunologic Response in Patients (pts) with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study
- (H22) **Smiroldo V et al.** Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (CAPTEM) in Patients with Metastatic Neuroendocrine Tumors (NETS). A 5-Years Single-Institution Experience
- (H23) **Strosberg J et al.** Patient-Reported Carcinoid Syndrome Symptom Improvement after Initiating Telotristat Ethyl in the Real World
- (H24) **Szpak W et al.** Response to Treatment and Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumours Treated with Lanreotide Autogel in South Africa
- (H25) **Villabona C et al.** Evaluation of the Use of Resources and Costs Associated with Uncontrolled or Controlled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs) in Spain: RECOSY Study

**I. MEDICAL TREATMENT - TARGETED THERAPIES**

- OA (I01)** **Apostolidis L et al.** Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium
- (I02) **Athar A et al.** Palliative Chemotherapy a Treatment Option for Large Cell Neuroendocrine Carcinoma
- PA (I03)** **Capdevila J et al.** Efficacy and Safety Analyses of the TALENT Trial (GETNE 1509): A Phase II Study of Lenvatinib in Patients (pts) with Advanced G1/G2 Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors
- (I04) **Chan D et al.** Age>70 Predicts Everolimus Toxicity in Patients with NEN: A Retrospective Review
- (I05) **De A et al.** Smart Polymeric Nanoparticles of Temozolomide for Enhancement of Brain Targeting?
- (I06) **Hermans B et al.** Prevalence and Prognostic Value of PD-L1 Expression in Molecular Subtypes of Metastatic Large Cell Neuroendocrine Carcinoma (LCNEC)
- (I07) **Kuznetsova A et al.** Efficiency of SUNITINIB in Treatment of PNETs Depending on Various Factors
- (I08) **Mauro C et al.** Opportunist Infections in Patients with Neuroendocrine Tumors Treated with Everolimus: A Multicenter Study
- (I09) **Molina-Cerrillo J et al.** TKI/mTOR Sequencing in Pancreatic Neuroendocrine Tumors (pNET): Experience in a Tertiary Referral Hospital
- (I10) **Morizane C et al.** A Phase II Study of Everolimus in Patients with Unresectable Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Contained Chemotherapy
- (I11) **Nunez JE et al.** The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors

**J. MEDICAL TREATMENT - OTHERS, NOT SPECIFIED**

- (J01) **Armentano DP et al.** Gamma-Glutamyl Transferase (GGT) as an Early Predictor of Better Progression-Free Survival in Well-Differentiated Gastroenteropancreatic Neuro-Endocrine Tumors (GEP-NET) in Different Lines of Treatment
- (J02) **Dou D et al.** The Role of TCM in the Treatment of Type 1 Gastric Neuroendocrine Tumor: A Clinical Observation of a Single Center in China
- (J03) **García-Garro S et al.** Direct Impact of Clinical Research in Metastatic G1 and G2 Neuroendocrine Tumors (NETs): A Cost-Effectiveness Analysis of Patient Care Outcomes and Cost Savings in a Real-Life Scenario of a Large Public University Hospital in Spain
- OA (J04)** **Godthelp A et al.** Social Consequences of Disease-Related Symptoms in Patients with a Metastatic Small Bowel Neuroendocrine Tumor: A Qualitative Study
- (J05) **Hayes AR et al.** Understanding Treatment Algorithms in Patients with Metastatic Pancreatic Neuroendocrine Tumours (mPNET)
- (J06) **Hernando J et al.** „Dones en Actiu“ (Active Women), A Collaborative Partnership between Patients, Nurses and Doctors in Neuroendocrine Tumors
- (J07) **Hörsch D et al.** Long-Term Treatment with Telotristat Ethyl (TE) in Patients with Carcinoid Syndrome (CS) Symptoms: Results from TELEPATH Study
- (J08) **Khan M et al.** Differential Diagnosis (DDx) of Carcinoid Syndrome Diarrhea (CSD): A Systematic Literature Review (SLR)

- (J09) **La Salvia A et al.** Ocular Metastases in Neuroendocrine Tumors Patients: Clinical Experience and Management
- (J10) **Laing E et al.** Exploring Nutrition Screening and Management Practices among Health Professionals Managing Patients with Neuroendocrine Tumours
- (J11) **Lamarca A et al.** Management of Bone Metastases (BMs) in Patients (pts) with Neuroendocrine Neoplasms (NENs): Findings from a Retrospective Study
- (J12) **McNamara MG et al.** Second-Line Treatment in Patients (pts) with Advanced Extra-Pulmonary Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC): A Systematic Review and Meta-Analysis
- (J13) **Pevny S et al.** Systemic Anti-Cancer Therapies Impair the Nutritional Status of Neuroendocrine Tumor Patients
- (J14) **Spada F et al.** An Italian Multicenter Study in Patients with Advanced Mixed Adeno-Neuroendocrine Carcinomas (MANECs) of the Gastro-Entero-Pancreatic Tract Treated with Chemotherapy
- (J15) **Walter T et al.** The Effect of Carcinoid Syndrome Diarrhea (CSD) Interventions on Patient Experience Outcomes: A Systematic Literature Review (SLR)
- (J16) **Xue B et al.** Clinical Value of Endoscopic Ultrasonography in Treatment of Rectal Neuroendocrine Neoplasms with Endoscopic Submucosal Dissection
- (J17) **Xue B et al.** Endoscopic Treatment of 46 Cases of Gastrointestinal Neuroendocrine Neoplasms
- (J18) **Yeung HM et al.** Characterizing Immunophenotyping Changes with Pembrolizumab (P) Therapy in Grade 3 Neuroendocrine Neoplasms (G3 NENs)

#### K. NUCLEAR MEDICINE - IMAGING AND THERAPY (PRRT)

- (K01) **Aalbersberg E et al.** Radiomics: A State-of-the-Art Tool for 68Ga-DOTATATE PET Imaging in NET
- PW** (K02) **Antwi K et al.** 68Ga-Exendin-4 PET/CT Specifically Detects Insulinomas in MEN-1 Patients
- (K03) **Armeni E et al.** Peptide Receptor Radionuclide Therapy (177Lutetium DOTATATE) as a Treatment Modality for Metastatic Pheochromocytoma (PCC) and Paraganglioma (PGL)
- (K04) **Bello P et al.** Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
- (K05) **Bhatt A et al.** Pancreatic Uptake in Ga-68 DOTATATE PET in a Series of Small Bowel Neuroendocrine Neoplasms: Metastasis, New Primary or Just Physiological Uptake?
- (K06) **Calabrò D et al.** 68Ga-DOTANOC Positive Neuroendocrine Skeletal Lesions: Does the Primary Tumour Show a Preferential CT Pattern?
- (K07) **Chan D et al.** Impact of [68Ga]-DOTATATE (DOTA) PET after Resection of Appendiceal NEN: A Retrospective Study
- (K08) **Chan D et al.** Quantitative Analysis of FDG PET in Neuroendocrine Neoplasms (NEN): Metabolic Tumour Volume Is a Predictor of Poor Prognosis
- (K09) **Chan D et al.** The Role of FDG and DOTATATE PET in Predicting PRRT Efficacy: A Quantitative Lesion-Based Analysis
- (K10) **Chirindel A et al.** Subacute and Long Term Hepatotoxicity Risk after 90Y- OR 177LU-DOTATOC Therapy – Is Hepatic Tumour Burden on 68Ga-DOTATOC PET/CT Predictive of Liver Dysfunction?
- (K11) **Cox N et al.** Ga-68 DOTATATE PET/CT: Is It Appropriate to Be Used as a Screening Imaging Modality in Patients with Raised Biochemical Markers and Non-Specific Symptoms?
- (K12) **De Dosso S et al.** Detection Rate of Unknown Primary Tumours by Using Somatostatin Receptor PET/CT in Patients with Metastatic Neuroendocrine Tumours: A Meta-Analysis
- (K13) **De Mestier L et al.** Correlation between Ki-67 and Uptake at 18FDG-PET in Pancreatic Neuroendocrine Tumors: A Lesion-by-Lesion Analysis
- (K14) **De Mestier L et al.** Prognostic Impact of Uptake at 18Fluoro-dihydroxy-phenylalanine (FDOPA-PET) in Advanced Small-Intestine Neuroendocrine Tumors (siNET)
- (K15) **Dioca MH et al.** Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) 90Y-Dotatoc in Neuroendocrine Tumors (NETs) Patients: Single-Institution Retrospective Analysis
- (K16) **Fatima A et al.** Analysing the Effectiveness Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. A Journey Towards Optimising the Treatment Options for NET
- (K17) **Fröss-Baron K et al.** Is 177Lu-DOTA-Octreotate Therapy Effective and Safe in Patients with Advanced Pancreatic Neuroendocrine Tumours Who Have Previously Undergone Chemotherapy?



- OA (K18)** **Goncalves I et al.** Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series
- (K19)** **Hung TJ et al.** Clinical Efficacy in Treatment of Metastatic Gastrinoma and Glucagonoma with Peptide Receptor Radionuclide Therapy (PRRT) - A Single Centre Experience
- (K20)** **Karfis I et al.** Combined Ga-DOTATATE and FDG PET Imaging Improves Prognostic Stratification In Metastatic Gastroenteropancreatic Neuroendocrine Neoplasias (GEP-NENs)
- (K21)** **Konsek S et al.** Usefulness of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)
- (K22)** **Kunikowska J et al.** Polish Multicenter Experience with Tandem Peptide Receptor Radionuclide Therapy Using 90Y/177Lu-DOTATATE in Neuroendocrine Tumors
- (K23)** **Laskaratos F et al.** Assessment of Changes in Mesenteric Fibrosis (MF) after Peptide Receptor Radionuclide Therapy (PRRT) in Midgut Neuroendocrine Tumours (NETs)
- (K24)** **Liberini V et al.** Can Texture Analysis Be Used for a Vivo “Imaging Biopsy” in Neuroendocrine Tumors? A First Step Feasibility Study with 68Ga-DOTATOC PET/CT
- (K25)** **Mapelli P et al.** Dual Tracer 68Ga-DOTATOC and 18F-FDG PET/CT for Preoperative Risk Assessment of Pancreatic Neuroendocrine Neoplasms (PanNENs)
- (K26)** **Mapelli P et al.** Texture Analysis of Dual Tracer 68Ga-DOTATOC and 18F-FDG PET/CT for Preoperative Risk Evaluation in Pancreatic Neuroendocrine Neoplasms (PanNENs): An Explorative Investigation
- (K27)** **Marin G et al.** Impaired Kidney Function Is Associated with Higher Absorbed Dose to Organs-at-Risk in 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT)
- (K28)** **Marques B et al.** 177Lu-DOTA-TATE Therapy in Midgut Neuroendocrine Tumours: Experience of a Tertiary Center
- (K29)** **Mitjavila M et al.** Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATE: Data from Spanish SEPTRALU Registry
- (K30)** **Nicolas G et al.** OPS-C-001: A Phase I/II Study to Investigate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor (SSTR)-Positive Neuroendocrine Tumours (NETs)
- (K31)** **Pilati E et al.** Impact of 68Ga DOTATOC PET/CT in the Therapeutic Management of Neuroendocrine Tumors
- (K32)** **Prinzi N et al.** Somatostatin Analogues (SSAs) in Association to Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Well-Differentiated (WD) Entero-Pancreatic Neuroendocrine Tumours (EP-NETs): A Monocentric Retrospective Study
- (K33)** **Puranik A et al.** Does Dual FDG and Ga-68 DOTANOC PET/CT Impact Survival in Patients with WHO Grade 2 GEP-NETs?
- (K34)** **Puranik A et al.** Peptide Receptor Radionuclide Therapy Using 177Lu and 90Y-DOTATATE in Metastatic Treatment-Refractory Medullary Thyroid Cancer
- (K35)** **Rottenburger C et al.** Evaluation of the CCK-2 Receptor Agonist 177Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma - Results of a Phase 0 „Lumed“ Study
- (K36)** **Saavedra C et al.** Current Experience in Heavily Pretreated Metastatic Neuroendocrine Tumors (NET) Treated with 177Lu-DOTATATE (LU). A Single Institution Experience
- (K37)** **Strosberg J et al.** LUTATHERA® Treatment Benefits Patients Even with Moderately Impaired Baseline Renal Function
- (K38)** **Sullivan L et al.** The Efficacy of Lutetium-177 DOTATATE in Refractory Symptoms of Functional Pancreatic Neuroendocrine Tumours
- OA (K39)** **Sundin A et al.** 11C-Hydroxy-Ephedrine-PET/CT for Diagnosis of Pheochromocytomas and Paragangliomas and for Characterization of Equivocal Adrenal Incidentalomas
- (K40)** **Sundlöv A et al.** Long-Term Follow-Up of Pituitary Function after Individualized PRRT with 177Lu-DOTATATE
- (K41)** **Zandee W et al.** Peptide Receptor Radionuclide Therapy with Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

#### L. SURGICAL TREATMENT AND ABLATIVE THERAPIES

- (L01)** **Andreasi V et al.** Long-Term Oncological Outcomes after Distal Pancreatectomy for Neuroendocrine Neoplasms: A Comparison between Minimally Invasive and Open Approach Using Propensity Score

- (L02) **Bassi N et al.** Outcomes of Surgery for Retroperitoneal and Proximal Vascular NET Associated Desmoplasia
- (L03) **Bongini M et al.** Y-90 Radioembolization of Liver Metastases from Neuroendocrine (NET) Tumors
- (L04) **Chorna N et al.** Pancreatic Neuroendocrine Tumors
- (L05) **Fatima A et al.** Finding the Options of Managing Duodenal Carcinoids in Pakistan. A Retrospective Study in a Territory Care Setup
- (L06) **Heidsma C et al.** Long-Term Quality of Life after Surgery for Pancreatic Neuroendocrine Tumors
- (L07) **Kaçmaz E et al.** Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis
- (L08) **Kong G et al.** Valvular Replacement in Patients with Carcinoid Heart Disease (CaHD) – Preliminary Surgical Experience
- (L09) **Lænkholm IT et al.** Gastroenteropancreatic (GEP) Mixed Neuroendocrine-Non-Endocrine Neoplasms (MiNEN)
- (L10) **Maggino L et al.** Cystic Pancreatic Neuroendocrine Neoplasms: A Multicenter International Cohort Study
- (L11) **Mao R et al.** Lymph Node Dissection Does Not Improve Survival in Patients with Pancreatic Neuroendocrine Tumors: A Study of the National Cancer Database
- (L12) **Masui T et al.** Ki-67 Index as a Guide to Surgical Management of Small Pancreatic Neuroendocrine Neoplasms for Lymph Node Metastasis
- (L13) **Milanetto AC et al.** Ampullary Neuroendocrine Neoplasms: Surgical Experience in Italy
- (L14) **Milanetto AC et al.** Changing Syndrome: A Focus on Pancreatico-Duodenal NeuroEndocrine Neoplasms
- (L15) **Milanetto AC et al.** Duodenal NeuroEndocrine Neoplasms: Retrospective Analysis of 33 Cases Diagnosed in a Single Centre
- (L16) **Milanetto AC et al.** Gonadal Metastases In Small Intestinal NeuroEndocrine Neoplasms
- (L17) **Milanetto AC et al.** Non-Insulinoma Organic Hyperinsulinism in Adults: A Challenging Diagnosis and Therapeutic Management
- (L18) **Milanetto AC et al.** Small Intestinal NeuroEndocrine Neoplasms in MEN-1 Syndrome: Could It Be MEN-4 Syndrome?
- (L19) **Miotto M et al.** Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
- (L20) **Monteleone M et al.** Recurrence after Liver Transplantation for Metastatic GEP-NET
- (L21) **Nappo G et al.** The Number of Metastatic Lymphnodes Is a Useful Predictive Factor for Recurrence after Surgery for Non-Metastatic Nonfunctional Neuroendocrine Tumor of the Pancreas
- (L22) **Nunez JE et al.** Prognostic Factors Associated with the Efficacy of Hepatic Artery Embolization in Patients with Neuroendocrine Tumors
- (L23) **Oleinikov K et al.** Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) as a Novel Therapeutic Approach in Highly-Selected Pancreatic Neuroendocrine Neoplasms (pNENs) Patients: Preliminary Report
- (L24) **Ricci C et al.** A Cure Model Survival Analysis of Patients Affected by Pancreatic Neuroendocrine Neoplasms: The Bologna ENETS Center Experience
- (L25) **Ricci C et al.** A Cure Model Survival Analysis of Patients Affected by Small Intestinal Neuroendocrine Neoplasms: The Bologna ENETS Center Experience
- (L26) **Ricci C et al.** Histopathological Diagnosis of Appendiceal Neuroendocrine Neoplasm: When to Perform Right Hemicolectomy? A Systematic Review and Meta-Analysis
- (L27) **Santucci N et al.** Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1. An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Cohort Study
- (L28) **Van Beek DJ et al.** The Role of Tumor Functionality on Survival in MEN1-Related Pancreatic Neuroendocrine Tumors: Non-Functioning Pancreatic Neuroendocrine Tumors Versus Insulinomas
- (L29) **Weaver H et al.** Glenfield Pulmonary Neuroendocrine Tumour Guidelines

#### M. NON DIGESTIVE NETS (BRONCHIAL, THYMIC, OTHERS) - DIAGNOSIS AND THERAPY

- (M01) **Athar A et al.** Neuroendocrine Carcinoma of the Breast – A Rare Clinical Entity
- (M02) **Bengueddach A et al.** Neuroendocrine Prostate Cancer: Molecular Features, Therapeutic Management and Future Directions; Two Cases Report

- (M03) **Ferolla P et al.** Population Data from Atlant, Phase 2 Study Combination Trial between Long Acting Somatostatin Analogue (SSA) Lanreotide (LAN) and Temozolomide (TMZ) in Progressive Thoracic (Lung/Thymus) Well Differentiated NET (Carcinoid) (TNETS)
- (M04) **Hernando J et al.** Long-Term Follow-Up (FU) in Patients (pts) with Primary Lung Carcinoid Tumors (LCT): Is It really Cost-Effective?
- (M05) **Patané A et al.** Predictive Value of Percentage of Ki-67 Expression in Bronchopulmonary Carcinoid Tumors
- (M06) **Łowczak A et al.** Evaluation of OS and PFS in Patients with Pulmonary Neoplasms Including LCNEC and NECG3

**N. ENDOCRINE MALIGNANCIES (MTC, PHEOCHROMOCYTOMA) - DIAGNOSIS AND THERAPY**

- (N01) **Armeni E et al.** Insight into the Management of Chromaffin Cell Derived Tumours - Experience from Two ENETS Centres of Excellence
- (N02) **Bengueddach A et al.** A Rare Case of Pheochromocytoma with Carcinoid Syndrome: A Case Report and Literature Review
- (N03) **Hayes AR et al.** Metastatic Medullary Thyroid Cancer (MTC): Is There a Role for Peptide Receptor Radionuclide Therapy (PRRT)?

**O. CASE REPORTS**

- (O01) **Abu-Hijlih R et al.** Primary Neuroendocrine Carcinoma of the Thymus
- (O02) **Aguirre-Allende I et al.** Surgery for Non-Functioning Pancreatic Neuroendocrine Tumour with Liver Metastases: A Case Report and Literature Review
- (O03) **Barquin A et al.** Prolonged Response to 177Lu-DOTATATE in a Patient with a Heavily Pre-treated Rectal NET
- (O04) **Bernardo YM et al.** Controlling Severe Hypoglycemia with Everolimus plus 177Lu-DOTATATE in Metastatic Insulinoma: Two Cases
- (O05) **Chen X et al.** Gallbladder Mixed Adenoneuroendocrine Carcinoma: A Case Report
- (O06) **Fatima A et al.** Appendiceal Neuroendocrine Tumor Causing Primary Infertility - A Case Report
- (O07) **Femia D et al.** Unexpected Expression of Estrogen and Progesterone Receptor (ER and PgR) and Response to Aromatase Inhibitors (AI) in Neuroendocrine Tumor (NET) of the Lung
- (O08) **Galesanu C et al.** Neuroendocrine Tumors of the Lung (Lu-NETs) - Case Report
- (O09) **González Devia D et al.** Recurrent Hypoglycemia Related by Sporadic Malignant Insulinomatosis: Case Report
- (O10) **Grimaldi F et al.** Continuous Glucose Monitoring in the Screening of Insulinomas
- (O11) **Hasanbegović M et al.** Sporadic Gastrinoma of Major Duodenal Papilla in Young Female Patient: When Proton Pump Inhibitor Withdrawal Opens a Search for Mystical Primary Lesion
- (O12) **Haydar Ali Tajuddin A et al.** Staged Inferior Vena Cava (IVC) Sampling for ACTH in a Von-Hippel-Lindau Syndrome (VHL) Patient with Cushing's Syndrome, Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma
- (O13) **Iorio J et al.** 68Ga-DOTA-TATE PET/CT Role in a Case Report of Transformation of Adenocarcinoma to Well-Differentiated Neuroendocrine Tumor
- (O14) **Karfis I et al.** Successful and Durable Glycemic-Disease Control after PRRT in a Patient with Malignant Insulinoma
- (O15) **Kehili H et al.** Neuroendocrine Tumor of the Gallbladder: 2 Cases Report
- (O16) **Kovacheva-Slavova M et al.** Multimodal Management of Neuroendocrine Lung Tumor with Liver Metastases – A Case Report
- (O17) **Lawal S et al.** An Interesting Case of Multiple Pancreatic Neuroendocrine Tumour: Normoglycaemic Glucagonoma with Concurrent Diagnosis of Gastrinoma
- (O18) **Lengyel I et al.** Severe Cushing's Disease Caused by Lung Neuroendocrine Tumor
- (O19) **Lengyel I et al.** Two Neuroendocrine Tumors in One Patient – A Case of Multiple Endocrine Neoplasia Type 1
- (O20) **Markovich A et al.** Pregnancy with the Use of Long-Acting SSA Administration: A Case Report
- (O21) **Mastrangelo L et al.** Combined Associating Right Trisectionectomy and Spleen Distal Pancreatectomy for a Rare Case of Ectopic Adrenocorticotrophic Hormone Syndrome Caused by a Metastatic Neuroendocrine Tumor of the Pancreas

- (O22) **Mollazadegan K et al.** Treatment Effect in Secondary High Grade Pancreatic Neuroendocrine Tumour (Pan-NET) - A Case Report
- (O23) **Moreira AP et al.** In Vivo Portrait of von Hippel-Lindau Syndrome with 68Ga-DOTANOC PET-CT
- (O24) **Myrehaug S et al.** Proof of Concept for Stereotactic Body Radiation Therapy in the Treatment of Functional Neuroendocrine
- (O25) **Patané A et al.** Diffuse Idiopathic Pulmonary Neuroendocrine Cells Hyperplasia (DIPNECH)/Tumorlets
- (O26) **Peralta Ferreira M et al.** Neuroendocrine Tumor of Unknown Primary Site?
- (O27) **Reher D et al.** Pancreatitis Due to Pancreatic Metastases of Small Bowel and Lung Neuroendocrine Tumors
- (O28) **Sakata K et al.** Thyrotropin and Thyrotropin-Releasing Hormone Co-Producing Pituitary Gangliocytoma: Case Report and Review of Literature
- (O29) **Soczomski P et al.** A Case Report of a Family with MEN 1 Syndrome and Renal Cancer – Should We Change Our Thinking about Typical MEN 1 Tumors?
- (O30) **Sripodok S et al.** A Case Report of Gallbladder Neuroendocrine Tumor
- (O31) **Valerieva Y et al.** Pancreatic Insulinoma – A Case of Three Small Tumors
- (O32) **Wang X et al.** S-1 and Temozolomide May Be an Effective Second-Line Treatment for Neuroendocrine Carcinoma of the Breast
- (O33) **Xue B et al.** Neuroendocrine Tumor at Rectum with Liver Metastasis: A Case Report
- (O34) **Yadlapalli CD et al.** A Rare Case of Metastatic High Grade (G3), Poorly Differentiated Insulinoma
- (O35) **Yang Z et al.** ACTH-Secreting Pancreatic Neoplasm Associated with Cushing Syndrome: Case Report
- (O36) **Yang Z et al.** Intraoperative Insulin Assay Combined with Occlusion of the Pancreas for Localization of an Occult Insulinoma - A Case Report

#### P. TRIALS IN PROGRESS/TRIALS IN CONCEPT

- (P01) **Bongiovanni A et al.** A Randomized Phase II Trial of CAPTEM or FOLFIRI as Second-Line Therapy in Neuroendocrine Carcinomas and Exploratory Analysis of the Predictive Role of PET Imaging and Biological Markers (SENECA Study)
- (P02) **Hernando J et al.** Phase II Multicohort Study of Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung and Gastroenteropancreatic (GEP) Origin (DUNE Trial, GETNE 1601)
- (P03) **Isyangulova A et al.** The Analysis of Mutations at Patients with Neuroendocrinal Tumors (P04 Kos-Kudła B et al. Lanreotide Autogel 120mg (LAN) in Patients (pts) with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Prospective Observational NETways Study
- (P05) **Lamarca A et al.** TELEFIRST | First-line Lanreotide(LAN) + Telotristat ethyl(TE) / Placebo(PBO) in Patients(pts) with Advanced Well-Differentiated Small Intestinal Neuroendocrine Tumours(siNET with Highly-Functioning Carcinoid Syndrome(CS): Randomized Phase III Trial
- (P06) **Singh S et al.** LUTATHERA® in First Line Therapy of G2 and G3 GEP-NET
- (P07) **Singh S et al.** LUTATHERA® in Lung and Rare NET
- (P08) **Virgolini I et al.** Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs
- (P09) **Zaheer S et al.** Ga-68 DOTATAPEPTIDE PET/CT and 131I-MIBG Scans to Determine Feasibility of PRRT in Neuroblastoma